11C-acetate for Treatment Response After Radiotherapy for HCC



Status:Terminated
Conditions:Liver Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/24/2017
Start Date:September 2015
End Date:October 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma

It is thought that PET of the abdomen with 11C Acetate will provide new information regarding
whether or not patient's have benefited from radiotherapy. To test this theory, the project
will evaluate the potential of 11C acetate to serve as an earlier and/or better signal of
treatment success.


Inclusion Criteria:

- > 18 years of age

- Subject is willing to participate in the study and has signed the study informed
consent

- Subject is available and willing to comply with the protocol evaluations

- Diagnosed hepatocellular carcinoma confined to a single lobe of the liver if
undergoing 90Y radioembolization

- Diagnosed hepatocellular carcinoma confined to the liver if undergoing Stereotactic
Body Radiation Therapy (SBRT)

- Under consideration for 90Y radioembolization or Stereotactic Body Radiation Therapy
(SBRT)

Exclusion Criteria:

- Pregnant or planning to become pregnant within the next 12 months or breast-feeding

- GFR < 45

- Life expectancy < 6 months

- Claustrophobic and cannot tolerate imaging procedures

- Weigh > 350 lb (upper weight limit of scanner beds)

- Special vulnerabilities (e.g. fetuses, neonatales, pregnant women, children,
prisoners, institutionalized individuals).
We found this trial at
1
site
Indiana University
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Phone: 317-948-6340
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials